- Home
- DFIN vs VRDN Comparison
DFIN vs VRDN Comparison
Compare DFIN & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DFIN
- VRDN
- Stock Information
- Founded
- DFIN 1983
- VRDN 2006
- Country
- DFIN United States
- VRDN United States
- Employees
- DFIN N/A
- VRDN N/A
- Industry
- DFIN Other Consumer Services
- VRDN Medical Specialities
- Sector
- DFIN Consumer Discretionary
- VRDN Health Care
- Exchange
- DFIN Nasdaq
- VRDN Nasdaq
- Market Cap
- DFIN 1.9B
- VRDN 1.6B
- IPO Year
- DFIN N/A
- VRDN N/A
- Fundamental
- Price
- DFIN $48.48
- VRDN $16.27
- Analyst Decision
- DFIN Strong Buy
- VRDN Buy
- Analyst Count
- DFIN 3
- VRDN 12
- Target Price
- DFIN $71.33
- VRDN $36.44
- AVG Volume (30 Days)
- DFIN 256.6K
- VRDN 941.3K
- Earning Date
- DFIN 02-18-2025
- VRDN 03-04-2025
- Dividend Yield
- DFIN N/A
- VRDN N/A
- EPS Growth
- DFIN 13.75
- VRDN N/A
- EPS
- DFIN 3.06
- VRDN N/A
- Revenue
- DFIN $781,900,000.00
- VRDN $302,000.00
- Revenue This Year
- DFIN $8.00
- VRDN $3.30
- Revenue Next Year
- DFIN $4.41
- VRDN N/A
- P/E Ratio
- DFIN $15.92
- VRDN N/A
- Revenue Growth
- DFIN N/A
- VRDN N/A
- 52 Week Low
- DFIN $47.94
- VRDN $11.40
- 52 Week High
- DFIN $71.01
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- DFIN 23.29
- VRDN 36.43
- Support Level
- DFIN $47.94
- VRDN $15.62
- Resistance Level
- DFIN $67.18
- VRDN $18.15
- Average True Range (ATR)
- DFIN 2.74
- VRDN 0.91
- MACD
- DFIN -2.41
- VRDN -0.20
- Stochastic Oscillator
- DFIN 2.47
- VRDN 14.48
About DFIN Donnelley Financial Solutions Inc.
Donnelley Financial Solutions Inc is a global risk and compliance solutions company. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. The company operates in four segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management, Investment Companies - Software Solutions and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States( US), Europe, Asia, Canada, and others, of which the US accounts for the vast majority of its total revenue.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.